傅永伦  /  主任医师

—— 硕士生导师 ——

专业型硕导

—— 硕士生招生专业 ——

妇产科学

—— 研究方向 ——

生殖内分泌，卵巢刺激新方案的探索性研究。

—— 学术任职 ——

第一届上海市医学会妊娠免疫专科分会委员； 第一届上海市中西医结合学会不孕不育专业委员会常务委员。

—— 科研项目 ——

(1) 上海市第一妇婴保健院院级课题，2023B03，晚卵泡期卵巢刺激方案在多囊卵巢综合征患者体外受精-胚胎移植中的临床应用研究，2024-01至2026-11，50万元，在研，主持 (2) 上海市浦东新区医联体项目，PDYLT2022-22,浦东新区不孕不育诊疗规范建立和专病联盟建设，2022-08至2023-07，9万元，已结题，主持 (3) 上海市第一妇婴保健院院级课题，2020RC02，晚卵泡期促排方案在卵巢储备功能低下患者中的应用，2020-05至2025-04，50万元，在研，主持

—— 学术论文 ——

(1) Zhu X, Lang J, Wang Q, Fu Y. Extended versus conventional letrozole regimen in patients with polycystic ovary syndrome undergoing their first ovulation induction cycle: a prospective randomized controlled trial. Hum Reprod Open. 2024;2024(3):hoae046. (IF=8.3) (2) Zhu X, Fu Y. Extending letrozole treatment duration is effective in inducing ovulation in women with polycystic ovary syndrome and letrozole resistance. Fertil Steril. 2023;119(1):107-113. (IF=6.7) (3) Zhu X, Ye J, Fu Y. Premature ovarian insufficiency patients with viable embryos derived from autologous oocytes through repeated oocyte retrievals could obtain reasonable cumulative pregnancy outcomes following frozen-embryo transfer. Ann Transl Med. 2021;9(7):539. (IF=3.616) (4) Zhu X, Ye H, Ye J, Fu Y. Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Ann Transl Med. 2021;9(5):387. (IF=3.616) (5) Xiuxian Zhu, Jing Ye, Yonglun Fu*. Late follicular phase ovarian stimulation without exogenous pituitary modulators, Front Endocrinol (Lausanne), 2020,11:487. (IF=5.555) (6) Xiuxian Zhu, Xiaole Zhang, Yonglun Fu*. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore), 2015, 94(21): e909. (IF=1.206)

—— 其他成果 ——

在国际上首次将天然孕激素应用于控制性卵巢刺激，设计“孕激素方案”；在此基础上，进一步研究设计出“晚卵泡期卵巢刺激方案”，该方案自卵泡中晚期启动，无需添加垂体调控剂，进一步拓展了卵巢刺激的灵活性；对来曲唑抵抗的PCOS患者，通过延长来曲唑使用时间，成功诱发排卵，有效降低了多卵泡发育率和OHSS发生风险。